Advertisement
Table 1 Comparison of clinical features between breast tumors associated or not with L3MBTL4 loss (determined by aCGH)
From: Loss, mutation and deregulation of L3MBTL4 in breast cancers
| Characteristics (N) | L3MBTL4 non deleted | L3MBTL4 deleted | p | odds ratio |
|---|---|---|---|---|
| N = 230 | N = 77 | |||
| Age (300) | 52 (22-84) | 51 (24-82) | 0.69 | |
| Histological type (255) | 0.57 | |||
| Ductal | 152 (78%) | 48 (79%) | ||
| Lobular | 15 (8%) | 5 (8%) | ||
| Medularry | 12 (6%) | 2 (3%) | ||
| Mixt | 8 (4%) | 3 (5%) | ||
| Other | 7(4%) | 3 (5%) | ||
| Clinical form (301) | 0.11 | 1.76 | ||
| IBC | 33 (15%) | 18 (23%) | (0.87-3.5) | |
| Non IBC | 191 (85%) | 59 (77%) | ||
| Pathological tumor size (240) | 0.052 | |||
| pT1 | 45 (25%) | 8 (14%) | ||
| pT2 | 95 (52%) | 28 (48%) | ||
| pT3 | 42 (23%) | 22 (38%) | ||
| Pathological axillary lymph node status (266) | 1.02E-02 | 0.46 | ||
| Negative | 96 (48%) | 20 (30%) | (0.24-0.85) | |
| Positive | 103 (52%) | 47 (70%) | ||
| SBR grade (267) | 1.15E-02 | |||
| 1 | 38 (19%) | 3 (5%) | ||
| 2 | 63 (31%) | 25 (38%) | ||
| 3 | 100 (50%) | 38 (58%) | ||
| ER (275) | 0.11 | 0.6 | ||
| Negative | 84 (40%) | 19 (29%) | (0.31-1.13) | |
| Positive | 125 (60%) | 47 (71%) | ||
| PR (264) | 0.32 | 0.74 | ||
| Negative | 96 (48%) | 26 (41%) | (0.4-1.36) | |
| Positive | 104 (52%) | 38 (59%) | ||
| P53 (192) | 0.39 | 1.38 | ||
| Negative | 87 (59%) | 30 (67%) | (0.65-3) | |
| Positive | 60 (41%) | 15 (33%) | ||
| Ki67 (217) | 0.23 | 0.64 | ||
| Negative | 53 (32%) | 12 (23%) | (0.28-1.36) | |
| Positive | 112 (68%) | 40 (77%) | ||
| ERBB2 (226) | 1 | 1.03 | ||
| Negative | 145 (85%) | 48 (86%) | (0.42-2.83) | |
| Positive | 25 (15%) | 8 (14%) | ||
| Molecular subtype (264) | 8.04E-04 | |||
| Basal | 63 (33%) | 17 (23%) | ||
| ERBB2 | 22 (12%) | 9 (12%) | ||
| Luminal A | 52 (27%) | 18 (25%) | ||
| Luminal B | 29 (15%) | 27 (37%) | ||
| Normal-like | 25 (13%) | 2 (3%) | ||
| Metastatic relapse (198) | 0.32 | 0.62 | ||
| no | 135 (88%) | 37 (82%) | (0.23-1.78) | |
| yes | 18 (12%) | 8 (18%) | ||
| Death from breast cancer (239) | 0.38 | 0.73 | ||
| no | 139 (77%) | 41 (71%) | (0.36-1.52) | |
| yes | 42 (23%) | 17 (29%) | ||
| 5 year-Metastasis-free survival (198) | 90% | 81% | 0.254 | |
| 5 year-Overall specific survival (239) | 78% | 73% | 0.271 |
